Thomas W P Friedl - JoVE Visualize

Showing results (41-50 of 66) with videos related to

Pageof 7

Sort By:

Breast (Edinburgh, Scotland)|April 8, 2016

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trialLukas Schwentner, Nadia Harbeck, Susanne Singer, et al.

Plos One|September 9, 2025

The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.

Plos One|November 19, 2025

Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.

Breast Cancer Research and Treatment|June 23, 2018

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatmentEmanuel C A Bauer, Fabienne Schochter, Peter Widschwendter, et al.

Translational Oncology|December 23, 2015

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast CancerBernadette A S Jäger, Charlotte Finkenzeller, Carolin Bock, et al.

Cancers|August 26, 2022

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A TrialElisabeth K Trapp, Peter A Fasching, Tanja Fehm, et al.

International Journal of Cancer|June 2, 2025

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.

Journal of the National Cancer Institute|May 17, 2014

Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast CancerWolfgang J Janni, Brigitte Rack, Leon W M M Terstappen, et al.

Clinical Breast Cancer|July 19, 2018

Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A TrialPhilip Hepp, Peter A Fasching, Matthias W Beckmann, et al.

Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:

Pageof 7

Breast (Edinburgh, Scotland)|April 8, 2016

Short term quality of life with epirubicin-fluorouracil-cyclophosphamid (FEC) and sequential epirubicin/cyclophosphamid-docetaxel (EC-DOC) chemotherapy in patients with primary breast cancer - Results from the prospective multi-center randomized ADEBAR trialLukas Schwentner, Nadia Harbeck, Susanne Singer, et al.

Plos One|September 9, 2025

The SURVIVE study (NCT05658172): Bringing breast cancer aftercare to the 21stcentury: Study protocol of a Phase III clinical trial comparing liquid biopsy guided vs. Standard of care surveillance for intermediate to high-risk breast cancer survivorsTatjana Braun, Sophia Huesmann, Kerstin Pfister, et al.

Plos One|November 19, 2025

Study Protocol of SURVIVE HERoes (NCT06643585): Trastuzumab Deruxtecan for molecular relapse in HER2+/ Low early breast cancer with ctDNA positivity after primary therapyKerstin Pfister, Thomas W P Friedl, Andreas Hartkopf, et al.

Breast Cancer Research and Treatment|June 23, 2018

Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatmentEmanuel C A Bauer, Fabienne Schochter, Peter Widschwendter, et al.

Translational Oncology|December 23, 2015

Estrogen Receptor and HER2 Status on Disseminated Tumor Cells and Primary Tumor in Patients with Early Breast CancerBernadette A S Jäger, Charlotte Finkenzeller, Carolin Bock, et al.

Cancers|August 26, 2022

Does the Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer Patients Predict the Site of First Metastasis-Results from the Adjuvant SUCCESS A TrialElisabeth K Trapp, Peter A Fasching, Tanja Fehm, et al.

International Journal of Cancer|June 2, 2025

Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patientsKathrin Niedermayer, Henning Schäffler, Georgios Vlachos, et al.

Journal of the National Cancer Institute|May 17, 2014

Circulating tumor cells predict survival in early average-to-high risk breast cancer patientsBrigitte Rack, Christian Schindlbeck, Julia Jückstock, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2016

Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast CancerWolfgang J Janni, Brigitte Rack, Leon W M M Terstappen, et al.

Clinical Breast Cancer|July 19, 2018

Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A TrialPhilip Hepp, Peter A Fasching, Matthias W Beckmann, et al.

Pageof 7